Improving decision-making for older adults with advanced kidney disease
Official title: A Communication-Priming Intervention to Improve Shared Decision-Making Between Older Adults With Advanced Chronic Kidney Disease and Clinicians: A Cluster-Randomized Controlled Trial
Run by The University of Hong Kong · NCT06799936 · Data updated 2026-11-12
This study is testing a new way to help older adults with advanced kidney disease make better decisions about their treatment by improving communication with their doctors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 280 (estimated) |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Status | Recruiting |
| Started | February 4, 2025 |
| Main results expected | April 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | September 8, 2026 |
| Trial ID | NCT06799936 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are older adults diagnosed with advanced CKD Stage 4 or 5 who are planning to discuss treatment options with their clinicians.
✕Probably not a fit
Patients who are eligible for kidney transplant, currently on dialysis, or lack decision-making capacity may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates a communication-priming intervention called 'CKD Jumpstart- Tips' designed to enhance shared decision-making between older adults with advanced chronic kidney disease (CKD) and their clinicians. The intervention aims to improve various aspects of the decision-making process, including communication quality, patient involvement, and adherence to treatment choices. By conducting a cluster-randomized controlled trial, the researchers will compare outcomes between patients receiving the intervention and those receiving usual care. Key metrics include shared decision-making levels, decisional conflict, and health-related quality of life.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the decision-making experience and health outcomes for older adults with advanced CKD.
How similar studies have gone: Other studies have shown success with communication-priming interventions in enhancing shared decision-making, suggesting this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria for the two groups of participants (i.e. Clinicians and Patients): 1. Clinicians \- Nephrology specialists or higher physician trainees who provide specialty care to older adults with advanced chronic kidney disease 2. Patients * Diagnosis of advanced CKD Stage 4 or 5 defined by estimated Glomerular Filtration Rate (eGFR) of ≤ 20 and a creatinine level ≥350 (umol/L) on two measurements at least 90 days apart in the prior year. * Chinese- or English-speaking * Able to provide written informed consent and complete questionnaires * Can be contacted by phone Exclusion criteria for patients: Patients will be excluded if they * have a confirmed advanced CKD treatment decision for dialysis, palliative care, or renal transplant documented in clinical notes * have initiated any of these treatments * lack decision-making capacity
Where it's running
-
Queen Mary Hospital
Hong Kong, Hong Kong Recruiting
Study contacts
- Principal investigator: Jacqueline KY Yuen, Dr — The University of Hong Kong
- Study coordinator: Jacqueline KY Yuen, Dr
- Email: jkyuen@hku.hk
- Phone: (852) 2255-4608
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Home-based exercise to boost fitness for people waiting for a kidney transplant
This study tests whether a 12-week, home-based exercise program plus a wearable activity tracker helps adults on the kidney transplant waiting list increase daily activity and improve physical function.
-
BZLF1 peptide vaccine with QS-21 to prevent EBV-related cancers in patients awaiting organ transplants
This early-phase trial tests a BZLF1-based vaccine (OSU-2131) with QS-21 to see if it is safe and can help prevent EBV infection and related cancers in healthy people and in patients waiting for a solid organ transplant.
-
Chronic Kidney Disease: Testing a Structured Agenda-Setting Tool for Advanced CKD Patients
We’re testing a simple, structured discussion tool called CKD Topics with adults with advanced CKD (stages 4–5) to see how well it works before a larger study.
-
Evaluating the effects of dapagliflozin on kidney function in advanced chronic kidney disease
This study is testing if the medication dapagliflozin can help slow down kidney problems and lower the risk of heart or kidney-related deaths in adults with advanced chronic kidney disease.
-
Telemonitoring platform for high-risk chronic kidney disease patients
This study is testing if a new virtual care platform can help people with advanced kidney disease stay healthier and avoid trips to the emergency room or hospital.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.